文献速递痛风与晶体性关节病

痛风达标降尿酸治疗中血清尿酸达标决定因素

Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.
PubMed 文献 · Arthritis Rheumatol · 2023-12-26

本研究利用比较达标治疗别嘌醇与非布司他的试验数据,分析痛风患者血清尿酸达标的相关因素。764例完成48周者中618例(81%)达标;多变量调整后,高龄、高教育程度和较好健康相关生活质量与达标几率较高相关,非白人种族、较高基线尿酸、存在痛风石和使用利尿剂与达标几率较低相关。慢性肾病、高血压、糖尿病和心血管疾病与达标无关。

要点

  • 764例完成48周者中618例(81%)达到血清尿酸目标。
  • 高龄、高教育程度和较好健康相关生活质量与达标几率较高相关。
  • 非白人种族、较高基线尿酸、痛风石和利尿剂使用与达标几率较低相关。

核心结论

  • 在接受达标降尿酸治疗的痛风患者中,若干患者层面因素可预测血清尿酸达标。

研究设计与样本

  • 利用比较达标治疗别嘌醇与非布司他的试验数据,纳入血清尿酸≥6.8 mg/dL的痛风患者,随机分配至别嘌醇或非布司他,第0至24周滴定,第25至48周维持。
  • 若第36、42和48周血清尿酸均值<6.0 mg/dL,或存在痛风石时<5 mg/dL,则视为达到血清尿酸目标。
  • 预先选定可能决定因素包括社会人口学、合并症、利尿剂使用、健康相关生活质量、体重指数和痛风指标,采用多变量逻辑回归评估,并额外分析考虑治疗依从性。

主要发现

  • 764例完成第48周的研究参与者中,618例(81%)达到血清尿酸目标。
  • 多变量调整后,与达标几率较高相关的因素包括高龄(每10年aOR 1.40)、高教育程度(aOR 2.02)和较好健康相关生活质量(每0.1单位aOR 1.17)。
  • 与达标几率较低相关的因素包括非白人种族(aOR 0.32-0.47)、较高基线血清尿酸(每1 mg/dL aOR 0.83)、存在痛风石(aOR 0.29)和使用利尿剂(aOR 0.52)。
  • 慢性肾病、高血压、糖尿病和心血管疾病等合并症与血清尿酸达标无关。
  • 考虑依从性的分析中结果无实质性改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Using trial data comparing treat-to-target allopurinol and febuxostat in gout, we examined participant characteristics associated with serum urate (SU) goal achievement. METHODS: Participants with gout and SU ≥6.8 mg/dL were randomized to allopurinol or febuxostat, titrated during weeks 0 to 24, and maintained weeks 25 to 48. Participants were considered to achieve SU goal if the mean SU from weeks 36, 42, and 48 was <6.0 mg/dL or <5 mg/dL if tophi were present. Possible determinants of treatment response were preselected and included sociodemographics, comorbidities, diuretic use, health-related quality of life (HRQoL), body mass index, and gout measures. Determinants of SU response were assessed using multivariable logistic regression with additional analyses to account for treatment adherence. RESULTS: Of 764 study participants completing week 48, 618 (81%) achieved SU goal. After multivariable adjustment, factors associated with a greater likelihood of SU goal achievement included older age (adjusted odds ratio [aOR] 1.40 per 10 years), higher education (aOR 2.02), and better HRQoL (aOR 1.17 per 0.1 unit). Factors associated with a lower odds of SU goal achievement included non-White race (aORs 0.32-0.47), higher baseline SU (aOR 0.83 per 1 mg/dL), presence of tophi (aOR 0.29), and the use of diuretics (aOR 0.52). Comorbidities including chronic kidney disease, hypertension, diabetes, and cardiovascular disease were not associated with SU goal achievement. Results were not meaningfully changed in analyses accounting for adherence. CONCLUSIONS: Several patient-level factors were predictive of SU goal achievement among patients with gout who received treat-to-target urate-lowering therapy (ULT). Approaches that accurately predict individual responses to treat-to-target ULT hold promise in facilitating personalized management and improving outcomes in patients with gout.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Helget LN, O'Dell JR, Newcomb JA, et al. Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout. Arthritis Rheumatol. 2023. PMID: 37842953. doi:10.1002/art.42731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。